The Department of Health and Human Services has placed therapeutic monoclonal antibodies (i.e. REGEN-COV, bamlanivimab/etesevimab) to treat COVID-19 infection on a state-administered allocation. Kettering Health regularly reviews restrictions of COVID-19 treatments, looking at supply chain considerations, patient volume, and current literature.
The Ohio Department of Health will allocate supply weekly to hospitals and health systems based on estimated allocation, current usage, and provider feedback.
Based on estimated allocation, current usage, and provider feedback, the Kettering Health Pharmacy and Therapeutics Committee (P&T) has approved changes to the COVID-19 monoclonal antibody (mAb) restrictions for both hospital and infusion center use.
Below is a summary of changes:
- Age criteria for treatment increased to ≥ 65 (formerly ≥ 50).
- BMI criteria for treatment and PEP increased to BMI ≥ 35 (formerly BMI ≥ 30).
- Patients 16 years and older may qualify in the Emergency Department (to align with inpatient use criteria).
An emergency P&T Therapeutic Interchange was also approved to dispense whichever monoclonal antibody product is available (REGEN-COV, bamlanivimab/etesevimab, etc.). Pharmacists will change orders Per Protocol as necessary (see attached TI document for equivalent dosing).Changes to EPIC referral forms and order panels will be live tomorrow, 12/16/2021, at approximately noon. Updated paper copies of the referral forms for treatment and PEP are attached for your reference. Please see attached order forms for the complete list of requirements for COVID-19 monoclonal antibody use.